Psilocybin

Psychedelics as an adjunctive therapy to psychiatric counseling may be feasible for anxiety and mood disorders, but proper blinding in future clinical trials presents an ongoing obstacle to wider acceptance, according to a speaker.

Treatment with psilocybin was linked to improvements in motor and non-motor symptoms of Parkinson’s disease, as well as associated psychiatric conditions, with sustained results up to 1 month, results of a pilot study show.

Psilocybin-assisted psychotherapy significantly improved a range of psychiatric symptoms among people with cancer, according to research published in Nature Mental Health.

Psilocybin-assisted therapy induced positive personality changes in adults with alcohol use disorder, which may help to improve long-term outcomes by limiting traits that encourage relapse such as impulsiveness, according to study results.

High-dose psilocybin showed the potential to treat depressive symptoms, although the effect size appeared small and comparable to that of escitalopram, according to results of a network meta-analysis published in The BMJ.

Mushroom-containing nootropic gummies sold at gas stations and smoke shops in Virginia contained unlabeled psilocybin and psilocin, according to results of an investigation published in Morbidity and Mortality Weekly Report.

SAN DIEGO — Patients with migraine who received daytime psilocybin experienced reduced REM sleep, with effects lasting beyond the day of administration, according to a poster at the American Headache Society Annual Scientific Meeting.

Enveric Biosciences announced it has signed a nonbinding term sheet to out-license a class of novel psilocin prodrugs to MindBio Therapeutics, an agreement that could yield more than $66 million in sales.

The FDA has granted breakthrough therapy designation to Cybin’s CYB003, a proprietary deuterated psilocybin analog in development for treatment of major depressive disorder, according to a company press release.

Incannex Healthcare has announced positive topline results from its phase 2 PsiGAD1 clinical trial of psilocybin for generalized anxiety disorder, reporting statistically significant improvement in anxiety scores compared with placebo.